These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
639 related items for PubMed ID: 15231011
1. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, Fracture Intervention Trial Study Group. J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011 [Abstract] [Full Text] [Related]
2. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group. J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012 [Abstract] [Full Text] [Related]
3. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515 [Abstract] [Full Text] [Related]
4. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA. J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495 [Abstract] [Full Text] [Related]
5. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH. Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890 [Abstract] [Full Text] [Related]
6. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, Ross PD, Baran D, FIT Research Group. J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637 [Abstract] [Full Text] [Related]
7. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J. J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288 [Abstract] [Full Text] [Related]
8. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB. Arch Intern Med; 1999 Sep; 157(22):2617-24. PubMed ID: 9531231 [Abstract] [Full Text] [Related]
9. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH. Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081 [Abstract] [Full Text] [Related]
11. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J. Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062 [Abstract] [Full Text] [Related]
18. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ. Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426 [Abstract] [Full Text] [Related]
19. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas PD. J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013 [Abstract] [Full Text] [Related]